Managing patients with FLT3-mutated AML can be challenging. Ensure you are up to date with the latest evidence and guideline recommendations for maintenance monotherapy with recently approved FLT3 inhibitors for patients with FLT3-mutated AML. Customized learning pathways based on the speed and accuracy of your answers will provide you with real-time feedback and resources targeted to your level of knowledge. This curated education covers outcomes from clinical trials, recent guideline updates, and insights on maintenance monotherapy recommendations and adverse event management for FLT3 inhibitors. Upon completion, you will receive a personalized downloadable resource with all of the information presented to you during the activity.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/incorporating-recently-approved-flt3-inhibitors-as-maintenance-therapy
- Start Date: 2024-09-26 05:00:00
- End Date: 2024-09-26 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 40000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest